Novel Targets Involved in Ferroptosis for Therapeutic Development in Oncology

Cumulus Oncology is developing anti‑cancer therapies for clinical settings in areas of high unmet need, with the aim of developing improved outcomes for cancer patients. In particular, the company is interested in the identification of specific molecular targets and biomarkers associated with ferroptosis, which allow for the development of targeted therapies.

Approaches of Interest:

• All cancers are within scope 
• Open to different modalities including small molecules, biologics and mRNA therapeutics, targeting any mechanism of ferroptosis
• Platforms that identify ferroptosis targets and platforms that help in deconvoluting the mechanism involved in ferroptosis are of high interest
• Research opportunities relating to combination of ferroptosis-inducing agents with conventional cancer therapies, such as chemotherapy and radiation are within scope
• Projects that have a clear line of sight will be prioritised

Out of Scope:

• Drug-repurposing, gene therapy and cell therapies

Developmental Stages of Interest:

• Basic research to preclinical studies is within scope
• Research with proof of concept will be prioritised 
• In vitro validation, such as cancer cell line studies, and in vivo validation are both of interest

Submission Information

Submissions of one-page, 200–300-word briefs are encouraged, along with any optional supplementary information e.g. relevant publications. Ideally, submissions should also include a data summary. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.